1. |
Díaz-González Á, Forner A, Rodríguez de Lope C, et al. New challenges in clinical research on hepatocellular carcinoma. Rev Esp Enferm Dig, 2016, 108(8): 485-493.
|
2. |
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015, 136(5): E359-E386.
|
3. |
Trinchet J C, Bourcier V, Chaffaut C, et al. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Hepatology, 2015, 62(3): 737-750.
|
4. |
Mcglynn K A, Petrick J L, London W T. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis, 2015, 19(2): 223-238.
|
5. |
Bruix J, Reig M, Sherman M. Evidence-Based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology, 2016, 150(4): 835-853.
|
6. |
Kim M J, Kim Y S, Cho Y H, et al. Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization. Korean J Intern Med, 2015, 30(3): 308-315.
|
7. |
Hayano K, Fuentes-Orrego J M, Sahani D V. New approaches for precise response evaluation in hepatocellular carcinoma. World J Gastroenterol, 2014, 20(12): 3059-3068.
|
8. |
Asman Y, Evenson A R, Even-Sapir E, et al. [18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco-ablative therapies for hepatocellular carcinoma. Liver Transpl, 2015, 21(5): 572-580.
|
9. |
Tsurusaki M, Okada M, Kuroda H, et al. Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor. J Gastroenterol, 2014, 49(1): 46-56.
|
10. |
Simoneau E, Hassanain M, Madkhali A, et al. (18)F-Fluorodeoxyglucose positron-emission tomography could have a prognostic role in patients with advanced hepatocellular carcinoma. Curr Oncol, 2014, 21(4): e551-e556.
|
11. |
Kuker R A, Mesoloras G, Gulec S A. Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease. Int Semin Surg Oncol, 2007, 4: 17.
|
12. |
Wolfort R M, Papillion P W, Turnage R H, et al. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade. Int Surg, 2010, 95(1): 67-75.
|
13. |
Lee J E, Jang J Y, Jeong S W, et al. Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography/computed tomography scan. World J Gastroenterol, 2012, 18(23): 2979-2987.
|
14. |
Huo Li, Guo Jinxia, Dang Yonghong, et al. Kinetic analysis of dynamic (11)C-acetate PET/CT imaging as a potential method for differentiation of hepatocellular carcinoma and benign liver lesions. Theranostics, 2015, 5(4): 371-377.
|
15. |
Cheung T T, Ho C L, Lo C M, et al. 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon's perspective. J Nucl Med, 2013, 54(2): 192-200.
|
16. |
Chotipanich C, Kunawudhi A, Promteangtrong C, et al. Diagnosis of hepatocellular carcinoma using C11 choline PET/CT: comparison with F-18 FDG, ContrastEnhanced MRI and MDCT. Asian Pac J Cancer Prev, 2016, 17(7): 3569-3573.
|
17. |
Attwa M H, El-Etreby S A. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol, 2015, 7(12): 1632-1651.
|
18. |
Ahn S Y, Lee J M, Joo I, et al. Prediction of microvascular invasion of hepatocellular carcinoma using gadoxetic acid-enhanced Mr and (18)F-FDG PET/CT. Abdom Imaging, 2015, 40(4): 843-851.
|
19. |
Detry O, Govaerts L, Deroover A, et al. Prognostic value of (18)F-FDG PET/CT in liver transplantation for hepatocarcinoma. World J Gastroenterol, 2015, 21(10): 3049-3054.
|
20. |
Lee J W, Hwang S H, Kim D Y, et al. Prognostic value of FDG uptake of portal vein tumor thrombosis in patients with locally advanced hepatocellular carcinoma. Clin Nucl Med, 2017, 42(1): e35-e40.
|
21. |
Mano Y, Aishima S, Kubo Y, et al. Correlation between biological marker expression and fluorine-18 fluorodeoxyglucose uptake in hepatocellular carcinoma. Am J Clin Pathol, 2014, 142(3): 391-397.
|
22. |
Song M J, Bae S H, Yoo I R, et al. Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol, 2012, 18(25): 3215-3222.
|
23. |
Lee J W, Oh J K, Chung Y A, et al. Prognostic significance of 18F-FDG uptake in hepatocellular carcinoma treated with transarterial chemoembolization or concurrent chemoradiotherapy: a multicenter retrospective cohort study. J Nucl Med, 2016, 57(4): 509-516.
|
24. |
Lee S D, Kim S H, Kim S K, et al. Clinical impact of 18F-Fluorodeoxyglucose positron emission tomography/computed tomography in living donor liver transplantation for advanced hepatocellular carcinoma. Transplantation, 2015, 99(10): 2142-2149.
|
25. |
Li Guang, Schmidtlein C R, Burger I A, et al. Assessing and accounting for the impact of respiratory motion on FDG uptake and viable volume for liver lesions in free-breathing PET using respiration-suspended PET images as reference. Med Phys, 2014, 41(9): 091905.
|